Results 21 to 30 of about 22,196 (255)
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
European Heart Journal, 2017 Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.
D. Hilfiker-Kleiner +20 more
semanticscholar +1 more source
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2023 Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan +3 more
doaj +1 more source
Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses
Frontiers in Veterinary Science, 2022 The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos +6 more
doaj +1 more source
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
American Journal of Perinatology Reports, 2018 Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon +2 more
doaj +1 more source
Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine
iScience, 2022 Summary: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D2 receptors (D2R), bromocriptine also targets the ...
Despoina Aslanoglou +14 more
doaj
American Journal of Physiology. Endocrinology and Metabolism, 2019 Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics.
Sarah N. Framnes-DeBoer +6 more
semanticscholar +1 more source
Bromocriptine-associated ototoxicity [PDF]
The Journal of Laryngology & Otology, 1984 AbstractThree patients treated with bromocriptine for chronic hepatic encephalopathy showed audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the hearing improved in all three patients when the bromocriptine dosage was reduced, thus suggesting that this drug may produce a reversible ototoxicity.
Lanthier, PL, Morgan, MY, Ballantyne, J
openaire +4 more sources
BMC Pharmacology and Toxicology, 2021 Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby +6 more
doaj +1 more source
ESC Heart Failure, 2018 Bromocriptine is thought to facilitate left ventricular (LV) recovery in peripartum cardiomyopathy (PPCM) through inhibition of prolactin secretion. However, this potential therapeutic effect remains controversial and was incompletely studied in diverse ...
M. Tremblay‐Gravel +24 more
semanticscholar +1 more source